Sysmex (OTCMKTS:SSMXY) Shares Gap Down – Here’s Why

Sysmex Corporation ADR (OTCMKTS:SSMXY) gapped down before the market opened on Monday . The stock had previously closed at $11.84, but opened at $11.18. Sysmex shares last traded at $11.61, with a volume of 880 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Zacks Research lowered shares of Sysmex from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold”.

Sysmex Stock Up 2.1%

The company has a quick ratio of 2.46, a current ratio of 3.26 and a debt-to-equity ratio of 0.12. The business has a 50-day simple moving average of $9.79 and a 200-day simple moving average of $9.18. The company has a market cap of $7.42 billion, a PE ratio of 28.07 and a beta of 1.05.

Sysmex (OTCMKTS:SSMXY) last announced its earnings results on Friday, August 7th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.07 by $0.02. Sysmex had a return on equity of 7.87% and a net margin of 7.62%.The business had revenue of $825.85 million during the quarter, compared to the consensus estimate of $741.67 million. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. Equities research analysts anticipate that Sysmex Corporation ADR will post 0.38 EPS for the current year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan?based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high?speed, high?volume testing for blood cell counts and differential analysis.